Drug Approvals International – Page 132 – All about Drugs Live by Dr Anthony Melvin Crasto

Process Development and Good Manufacturing Practice Production of a Tyrosinase Inhibitor via Titanium-Mediated Coupling between Unprotected Resorcinols and Ketones

(S)-4-(2,4-Dihydroxyphenyl)-N-(1-phenylethyl)piperidine-1-carboxamide (1) In a………………….. to yield crude 1 (3.51 kg, 77%, 97.7 A% purity). Recrystallization: In a 100 L double jacketed reactor were charged crude 1 (3.51 kg, 10.31 mol, 1.0 equiv), iPrOH (27.0 L, 7.5 vol), AcOH (74.1 g), and water (27.0 L, 7.5 vol). The suspension was warmed to reflux and turned to …

Enantioselective synthesis of a cyclobutane analogue of Milnacipran

(1R,2S)-2-(Aminomethyl)-N,N-diethyl-1 phenylcyclobutanecarboxamide (19) 1 H NMR (CDCl3) δ 7.36–7.33 (m, 4H), 7.25–7.21 (m, 1H), 3.51–3.43 (qd, J = 13.8 Hz, 6.8 Hz, 1H), 3.15–2.87 (m, 7H), 2.81–2.72 (m, 2H), 2.23–2.14 (m, 1H), 2.04–1.97 (m, 1H), 1.62 (tdd, J = 10.5 Hz, 5.7 Hz, 2.6 Hz, 1H), 1.07 (t, J = 7.1 Hz, 3H), 0.35 …

Debio-1452

Debio-1452, AFN 1252 AFN-1252; UNII-T3O718IKKM; API-1252; CAS 620175-39-5; CHEMBL1652621; (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide MFC22 H21 N3 O3 2-Propenamide, N-methyl-N-[(3-methyl-2-benzofuranyl)methyl]-3-(5,6,7,8-tetrahydro-7-oxo-1,8-naphthyridin-3-yl)-, (2E)- MW375.42 Phase 2, clinical trials for the oral treatment of staphylococcal infections, including hospital and community-acquired MRSA and acute bacterial skin and skin structure infections Qualified Infectious Disease Product designation GlaxoSmithKline plc INNOVATOR Debiopharm SA, Melioidosis, Enoyl ACP reductase Fabl …

FDA approves new drug to treat multiple sclerosis Ocrevus (ocrelizumab)

FDA approves new drug to treat multiple sclerosis 03/29/2017 On March 28, the U.S. Food and Drug Administration approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). This is the first drug approved by the FDA for PPMS. Ocrevus is an intravenous infusion given …

QUILSECONAZOLE, VT 1129, New Patent, WO, 2017049080, Viamet

VT 1129 BENZENE SULFONATE CAS 1809323-18-9 VT 1129 1340593-70-5 CAS MF C22 H14 F7 N5 O2, MW 513.37 2-Pyridineethanol, α-(2,4-difluorophenyl)-β,β-difluoro-α-(1H-tetrazol-1-ylmethyl)-5-[4-(trifluoromethoxy)phenyl]-, (αR)- R ISOMER ROTATION + QUILSECONAZOLE, VT-1129 Viamet, in collaboration with Therapeutics for Rare and Neglected diseases, is investigating quilseconazole benzenesulfonate (VT-1129), a small-molecule lanosterol demethylase (CYP51) inhibitor, developed using the company’s Metallophile technology, for treating fungal …

FDA approves new eczema drug Dupixent (dupilumab)

FDA approves new eczema drug Dupixent 03/28/2017 The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or …

TRIENTINE HYDROCHLORIDE, 塩酸トリエンチン , 曲恩汀

TRIENTINE Molecular Formula C6H18N4 Average mass 146.234 Da 112-24-3 CAS 曲恩汀, KD-034, MK-0681, MK-681, TECZA, TETA, TJA-250 1,2-Ethanediamine, N1,N2-bis(2-aminoethyl)- 1,8-diamino-3,6-diazaoctane TRIENTINE HYDROCHLORIDE Molecular Formula C6H19ClN4 Average mass 182.695 Da 38260-01-4 CAS Launched – 1986 VALEANT, WILSONS DISEASE 塩酸トリエンチン Trientine Hydrochloride C6H18N4▪2HCl : 219.16 [38260-01-4] Aton Pharma, a subsidiary of Valeant Pharmaceuticals, has developed and launched Syprine, a capsule formulation of trientine hydrochloride, for treating Wilson disease. Triethylenetetramine, …

SEN 826

SEN 826 CAS 1160833-51-1 C25 H31 N5 O, 417.55 Methanone, [1-[3-(1-methyl-1H-benzimidazol-2-yl)phenyl]-4-piperidinyl](4-methyl-1-piperazinyl)- CAS HBr SALT 1612250-71-1 WO2009074300 product patent Russell John Thomas, Mohr Gal.La Pericot, Giacomo Minetto, Annette Cornelia Bekker, Pietro Ferruzzi, Applicant Siena Biotech S.P.A. Siena Biotech S.p.A. operates as a drug discovery and development company which develops a portfolio of disease modifying small molecule therapeutics …

FDA approves first treatment Bavencio (avelumab)for rare form of skin cancer

Read at……https://www.pfizer.com/files/news/asco/Merck-PfizerAlliance_AvelumabFactSheet_19May2015US.pdf FDA approves first treatment for rare form of skin cancer 03/23/2017 The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is …

FDA approves drug Xadago (Safinamide, сафинамид , سافيناميد , 沙非胺 , ) to treat Parkinson’s disease

Safinamide Molecular Formula C17H19FN2O2 Average mass 302.343 Da (2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide 133865-89-1 , сафинамид , سافيناميد , 沙非胺 , EMD-1195686, ZP-034, FCE-28073(R-isomer), PNU-151774E, NW-1015, FCE-26743 CAS 202825-46-5 (mesylate) SEE BELOW (+)-(S)-2-[[p-[(m-fluorobenzyl)oxy]benzyl]amino]propionamide monomethanesulfonate Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate Molecular Weight 398.45 Formula C17H19FN2O2 ● CH4O3S CAS 202825-46-5 (Safinamide Mesylate) Safinamide is a white to off-white, non-hygroscopic crystalline solid. It shows pH dependent solubility in aqueous buffers due …